DGAP-News Mainz Biomed Announces the Closing of its $25.8 Million Public Follow-on Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares
DGAP-News: Mainz BioMed N.V. / Key word(s): Capital Increase
Mainz Biomed Announces the Closing of its $25.8 Million Public Follow-on Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Proceeds Allocated to Development of Recently Acquired mRNA Biomarkers and Launch of Clinical Studies to Support ColoAlert's FDA Submission
BERKELEY, US - MAINZ, Germany - JANUARY 28, 2022 - Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the closing of its underwritten public follow-on offering (the "Follow-on Offering") of 1,725,000 ordinary shares at a public offering price of US$15.00 per ordinary share (the "Offering Price"). The aggregate gross proceeds to Mainz Biomed were $25,875,000 before deducting underwriting discounts and commissions and other offering expenses payable. This included the exercise in full by the underwriters of their option to purchase 225,000 additional shares of common stock.
Boustead Securities, LLC acted as the sole underwriter for the offering. Ortoli Rosenstadt LLP served as counsel to Mainz Biomed. Sichenzia, Ross and Ference LLP served as counsel to the underwriter.
The offering was being made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained, when available, from Boustead Securities, LLC, via email: email@example.com or by calling +1 (949) 502-4408 or standard mail at Boustead Securities, LLC, Attn: Equity Capital Markets, 6 Venture, Suite 395, Irvine, CA 92618, USA. In addition, a copy of the final prospectus, when available, relating to the offering may be obtained via the SEC's website at www.sec.gov.